Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011;21(6):422-41; quiz 442-3.

Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations

T Caballero  1 , M L Baeza, R Cabañas, A Campos, S Cimbollek, C Gómez-Traseira, T González-Quevedo, M Guilarte, J Jurado-Palomo, J I Larco, M C López-Serrano, M López-Trascasa, C Marcos, J M Muñoz-Caro, M Pedrosa, N Prior, M Rubio, A Sala-Cunill; Spanish Study Group on Bradykinin-Induced Angioedema (SGBA)
Affiliations
  • PMID: 21995176
Free article
Review

Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations

T Caballero et al. J Investig Allergol Clin Immunol. 2011.
Free article

Erratum in

  • J Investig Allergol Clin Immunol. 2012;22(2):3 p following 153

Abstract

Background: There are no previous Spanish guidelines or consensus statements on bradykinin-induced angioedema.

Aim: To draft a consensus statement on the management and treatment of angioedema mediated by bradykinin in light of currently available scientific evidence and the experience of experts. This statement will serve as a guideline to health professionals.

Methods: The consensus was led by the Spanish Study Group on Bradykinin-Induced Angioedema, a working group of the Spanish Society of Allergology and Clinical Immunology. A review was conducted of scientific papers on different types of bradykinin-induced angioedema (hereditary and acquired angioedema due to C1 inhibitor deficiency, hereditary angioedema related to estrogens, angioedema induced by angiotensin-converting enzyme inhibitors). Several discussion meetings were held to reach the consensus.

Results: Treatment approaches are discussed, and the consensus reached is described. Specific situations are addressed, namely, pregnancy, contraception, travelling, blood donation, and organ transplantation.

Conclusions: A review of and consensus on treatment of bradykinin-induced angioedema is presented.

PubMed Disclaimer

Publication types